In Brief This Week: Gen-Probe; CardioDx; Scripps Florida, Hanley Center | GenomeWeb

NEW YORK (GenomeWeb News) – Gen-Probe this week said that it has begun a clinical study of its Progensa PCA3 assay, a molecular test for determining the need for a repeat prostate biopsy. The firm said that the trial would be conducted to support an application to the US Food and Drug Administration for clearance of the assay.

Gen-Probe said that it expects to enroll around 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites. It expects the trial to conclude in less than a year, after which it will file the application with FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.